Compare POWL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POWL | NUVL |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.8B |
| IPO Year | 1995 | 2021 |
| Metric | POWL | NUVL |
|---|---|---|
| Price | $185.89 | $103.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $427.00 | $134.13 |
| AVG Volume (30 Days) | 188.8K | ★ 541.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 20.91 | N/A |
| EPS | ★ 3.40 | N/A |
| Revenue | ★ $448,716,000.00 | N/A |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $8.77 | $1,165.56 |
| P/E Ratio | $161.12 | ★ N/A |
| Revenue Growth | ★ 13.34 | N/A |
| 52 Week Low | $154.50 | $55.54 |
| 52 Week High | $612.50 | $113.02 |
| Indicator | POWL | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 22.24 | 56.58 |
| Support Level | N/A | $101.37 |
| Resistance Level | $279.77 | $107.13 |
| Average True Range (ATR) | 30.71 | 3.52 |
| MACD | -22.31 | 1.02 |
| Stochastic Oscillator | 2.15 | 71.98 |
Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company's principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States, and the rest from Canada, Europe, Asia Pacific, and other regions.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.